Itacitinib Adipate

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, City of Hope Medical Center

Conditions

Acute LeukemiaBronchiolitis ObliteransHematologic and Lymphocytic DisorderMyelodysplastic SyndromePrimary MyelofibrosisSecondary Myelofibrosis

Phase 1

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

TerminatedNCT04239989

M.D. Anderson Cancer CenterBronchiolitis Obliterans

Start: 2021-10-08End: 2025-10-31Updated: 2025-11-07

Phase 2

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

CompletedNCT04339101

City of Hope Medical CenterAcute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome +2

Start: 2020-11-11End: 2025-10-09Updated: 2026-03-30

Related Papers

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood2024-11-05

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood2022-11-152 citations